Walleye Capital LLC Inhibrx, Inc. Transaction History

Walleye Capital LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $26.2 Million - $31.6 Million	800,000 New	800,000 $28 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $594,468 - $993,044	37,744 Added 114.01%	70,850 $1.3 Million
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $2.03 Million - $3.33 Million	-119,746 Reduced 78.34%	33,106 $859,000
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $998,698 - $1.47 Million	-54,130 Reduced 26.15%	152,852 $2.88 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $1.96 Million - $3.24 Million	97,166 Added 88.48%	206,982 $5.1 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $482,631 - $1.03 Million	41,678 Added 61.17%	109,816 $1.97 Million
Q2 2022 Aug 08, 2022	SELL	$8.52 - $25.26 $361,196 - $1.07 Million	-42,394 Reduced 38.35%	68,138 $773,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $1.09 Million - $2.37 Million	54,999 Added 99.04%	110,532 $2.46 Million
Q4 2021 Mar 03, 2022	BUY	$26.75 - $46.02 $1.49 Million - $2.56 Million	55,533 New	55,533 $2.43 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.